Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

The role of GABPA,GPD1L and BRD9 in renal cancer progression and metasasis

ABSTRACT: The role of GABPA,GPD1L and BRD9 in renal cancer progression and metasasis

PROVIDER: PRJNA695548 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR13573042_1.fastq.gz	Fastqsanger.gz
	SRR13573042_2.fastq.gz	Fastqsanger.gz
	SRR13573043_1.fastq.gz	Fastqsanger.gz
	SRR13573043_2.fastq.gz	Fastqsanger.gz
	SRR13573044_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 24

Similar Datasets

The role of GABPA,GPD1L and BRD9 in renal cancer progression and metasasis

Project description:RNAseq was performed on the cells with GABPA knockdown, the cells with GPD1L knockdown, the cells with BRD9 knockdown and the control cells.

2022-05-18 | GSE165728 | GEO

BRD9 is a regulator of androgen receptor signaling and prostate cancer progression - ChIP-Seq

Project description:BRD9 and BRD4 ChIP-Seq in LNCaP prostate cancer cells

2020-12-28 | GSE146623 | GEO

Role of copper in progression of clear cell renal cell carcinoma [Spatial transcriptomics]

Project description:Role of copper in progression of clear cell renal cell carcinoma [Spatial transcriptomics]

| PRJNA1052130 | ENA

Role of copper in progression of clear cell renal cell carcinoma [RNA-seq]

Project description:Role of copper in progression of clear cell renal cell carcinoma [RNA-seq]

| PRJNA1051628 | ENA

BRD9 is a regulator of androgen receptor signaling and prostate cancer progression

Project description:BRD9 is a regulator of androgen receptor signaling and prostate cancer progression

| PRJNA611525 | ENA

AIB1D4 role in early breast cancer progression

Project description:AIB1D4 role in early breast cancer progression

| PRJNA578942 | ENA

The ncBAF complex regulates transcription in AML through H3K27ac sensing by BRD9 (CUT&Run)

Project description:The non-canonical BAF complex (ncBAF) subunit BRD9 is essential for acute myeloid leukemia (AML) cell viability but has an unclear role in leukemogenesis. Because BRD9 is required for ncBAF complex assembly through its DUF3512 domain, precise bromodomain inhibition is necessary to parse the role of BRD9 as a transcriptional regulator from that of a scaffolding protein. To understand the specific role of BRD9 bromodomain function in regulating AML, we selected a panel of five AML cell lines with distinct driver mutations, disease classifications, and genomic aberrations and subjected them to short-term BRD9 bromodomain inhibition. We characterized the bromodomain-dependent growth of these cell lines, identifying a dependency in AML cell lines but not HEK293T cells. To define a mechanism through which BRD9 maintains AML cell survival, we examined nascent transcription, chromatin accessibility, and ncBAF complex binding genome-wide after bromodomain inhibition. We identified extensive regulation of transcription by BRD9 bromodomain activity, including repression of myeloid maturation factors and tumor suppressor genes, while standard AML chemotherapy targets (Bcl2, Btk, Kit) were repressed by inhibition of the BRD9 bromodomain. BRD9 bromodomain activity maintained accessible chromatin at both gene promoters and gene-distal putative enhancer regions, in a manner that qualitatively correlated with enrichment of BRD9 binding. Furthermore, we identified reduced chromatin accessibility at GATA, ETS, and AP-1 motifs and increased chromatin accessibility at SNAIL-, HIC-, and TP53-recognized motifs after BRD9 inhibition. We interpret these data as signifying a role for BRD9 in regulating the differentiation block that is common to all AML subtypes through modulation of accessibility at hematopoietic transcription factor binding sites.

2023-10-20 | GSE241425 | GEO

The ncBAF complex regulates transcription in AML through H3K27ac sensing by BRD9 (ATAC-Seq)

Project description:The non-canonical BAF complex (ncBAF) subunit BRD9 is essential for acute myeloid leukemia (AML) cell viability but has an unclear role in leukemogenesis. Because BRD9 is required for ncBAF complex assembly through its DUF3512 domain, precise bromodomain inhibition is necessary to parse the role of BRD9 as a transcriptional regulator from that of a scaffolding protein. To understand the specific role of BRD9 bromodomain function in regulating AML, we selected a panel of five AML cell lines with distinct driver mutations, disease classifications, and genomic aberrations and subjected them to short-term BRD9 bromodomain inhibition. We characterized the bromodomain-dependent growth of these cell lines, identifying a dependency in AML cell lines but not HEK293T cells. To define a mechanism through which BRD9 maintains AML cell survival, we examined nascent transcription, chromatin accessibility, and ncBAF complex binding genome-wide after bromodomain inhibition. We identified extensive regulation of transcription by BRD9 bromodomain activity, including ATACseq_Repression of myeloid maturation factors and tumor suppressor genes, while standard AML chemotherapy targets (Bcl2, Btk, Kit) were ATACseq_Repressed by inhibition of the BRD9 bromodomain. BRD9 bromodomain activity maintained accessible chromatin at both gene promoters and gene-distal putative enhancer regions, in a manner that qualitatively correlated with enrichment of BRD9 binding. Furthermore, we identified reduced chromatin accessibility at GATA, ETS, and AP-1 motifs and increased chromatin accessibility at SNAIL-, HIC-, and TP53-recognized motifs after BRD9 inhibition. We interpret these data as signifying a role for BRD9 in regulating the differentiation block that is common to all AML subtypes through modulation of accessibility at hematopoietic transcription factor binding sites.

2023-10-20 | GSE241424 | GEO

The ncBAF complex regulates transcription in AML through H3K27ac sensing by BRD9 (TT-Seq)

2023-10-20 | GSE241427 | GEO

Dynamic partitioning of branched-chain amino acids- derived nitrogen supports renal cancer progression

Project description:Metabolic reprogramming is critical for tumor initiation and progression. However, the exact impact of specific metabolic changes on cancer progression is poorly understood. Here, we integrate multimodal analyses of primary and metastatic clonally-related clear cell renal cancer cells (ccRCC) grown in physiological media to identify key stage-specific metabolic vulnerabilities. We show that a VHL loss-dependent reprogramming of branched-chain amino acid catabolism sustains the de novo biosynthesis of aspartate and arginine enabling tumor cells with the flexibility of partitioning the nitrogen of the amino acids depending on their needs. Importantly, we identify the epigenetic reactivation of argininosuccinate synthase (ASS1), a urea cycle enzyme suppressed in primary ccRCC, as a crucial event for metastatic renal cancer cells to acquire the capability to generate arginine, invade in vitro and metastasize in vivo. Overall, our study uncovers a mechanism of metabolic flexibility occurring during ccRCC progression, paving the way for the development of novel stage-specific therapies.

2022-11-09 | PXD037464 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data